Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa)

Massimo Franchini, Pier Mannuccio Mannucci

Research output: Contribution to journalReview articlepeer-review


Introduction: The development of inhibitors against infused factor VIII (FVIII) has a detrimental impact on health and quality of life of patients with hemophilia A. Several observational studies and a recently published randomized trial indicate that the inhibitor risk in previously untreated patients (PUPs) is higher following the use of recombinant FVIII (rFVIII) products compared with plasma-derived FVIII concentrates. There is currently a great interest towards newer rFVIII products that adopt various technological solutions to reduce the inhibitor risk. Areas covered: This review describes the efficacy and safety of simoctocog alfa (Nuwiq), a human cell-line derived rFVIII developed for the prevention and treatment of bleeding in hemophilia A patients. Particular relevance will be given to the safety aspects of this product, with special emphasis on the rate of inhibitor development, presenting the results of the phase II and III clinical trials on previously treated patients (PTPs) and the interim data from the phase III trial on PUPs. Expert opinion: The final results from PTP studies and the preliminary data from the PUP study document the high efficacy and safety profile of this rFVIII product, which has the potential to reduce the inhibitor risk in PUPs with severe hemophilia A.

Original languageEnglish
Pages (from-to)405-410
Number of pages6
JournalExpert Opinion on Drug Safety
Issue number3
Publication statusPublished - Mar 4 2017


  • Hemophilia A
  • human recombinant FVIII
  • inhibitors
  • safety
  • therapy

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa)'. Together they form a unique fingerprint.

Cite this